Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes

Volume: 9, Issue: 1, Pages: e001731 - e001731
Published: Jan 1, 2021
Abstract
Background Immune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve with corticosteroids and requires additional immunosuppression is termed steroid-refractory ICI-pneumonitis. Herein, we report the clinical features, management and outcomes for patients treated with intravenous immunoglobulin (IVIG), infliximab, or the combination of IVIG and infliximab for steroid-refractory ICI-pneumonitis. Methods Patients with...
Paper Details
Title
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
Published Date
Jan 1, 2021
Volume
9
Issue
1
Pages
e001731 - e001731
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.